Patient-Defined Treatment Success and Preferences in Stage IV Lung Cancer Patients

N/AUnknownNCT02190864

University of Nebraska210 enrolled

Overview

Our long-term goal is to integrate non-small cell lung cancer patient treatment preferences into clinical treatment planning.

The following specific aims are proposed: Aim 1: Determine whether individual patients' preferences, characteristics, and treatment experiences affect the definition of treatment success. Aim 2: Determine how to best predict real-life patients' treatment choices based on patients' preferences of adverse events. Aim 3: Determine whether physicians are likely to change their oncologic clinical practice after receiving a detailed communication of their patients' preferences of adverse events.

Study Type

OBSERVATIONAL

Enrollment

210

Conditions

Particularly Rural/Urban Residence Gender Age FACT-TOI Scores Comorbid Conditions

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Willing and able to provide consent * Greater than or equal to 19 years of age * Diagnosed with stage IV non-small cell lung cancer (NSCLC) * Able to understand spoken English * Eligible to undergo chemotherapy for stage IV NSCLC, to include, but not limited to, those who: 1. have not yet started chemo 2. are currently undergoing chemo for stage IV NSCLC 3. have completed first line stage IV NSCLC chemo or progressed to maintenance for stage IV NSCLC within the last 30 days 4. elect to have chemo elsewhere -- not at one of the study sites 5. decline chemo Exclusion Criteria: * Age \<19 years * Not willing and/or able to provide consent * Not able to understand spoken English * Not eligible to undergo chemotherapy for stage IV NSCLC

Locations (8)

Moffitt Cancer Center

Tampa, Florida, United States

RECRUITING

Kansas City VA Medical Center

Kansas City, Missouri, United States

RECRUITING

Saint Francis Cancer Treatment Center

Outcomes

Primary Outcomes

Patient-defined "treatment success"

In advanced stage NSCLC patients does patient-defined "treatment success" differ when both survival and patient preferences of adverse events are accounted for, compared to when success is measured solely by survival? And does it also differ based on individual patient characteristics?

Time frame: Baseline

Patients' will to experience adverse events

Will the serious adverse events that an advanced stage NSCLC patient is willing to experience as part of his/her treatment differ after a real-life treatment experience, compared to before treatment?

Time frame: Baseline

Secondary Outcomes

Summary score derived from patient preferences of adverse events

In advanced stage NSCLC patients, is a summary score derived from patient preferences of adverse events comparable to a real-life treatment scenario?

Time frame: Up to three months

Central Contacts

KM Munirul Islam, MD, PhD

CONTACT

402-559-8283 kmislam@unmc.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.